235. Hypoparathyroidism Clinical trials / Disease details
Clinical trials : 88 / Drugs : 107 - (DrugBank : 24) / Drug target genes : 5 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05654701 (ClinicalTrials.gov) | March 2023 | 8/12/2022 | Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism | Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism | Hypoparathyroidism | Drug: Palopegteriparatide (TransCon PTH) | Ascendis Pharma Bone Diseases A/S | NULL | Available | 18 Years | N/A | All | NULL |